Research progress of sequential immunotherapy for neuromyelitis optica spectrum disorders in children / 中华实用儿科临床杂志

ABSTRACT

Pediatric neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory demyelinating di-sease spectrum of the central nervous system, mainly involving the optic nerve and spinal cord.Due to the high disability and recurrence rate, sequential immunotherapy is usually needed to prevent the recurrence of NMOSD after acute treatment.Among the commonly used immune suppressants, Rituximab and Mycophenolate mofetil are the preferred drugs due to the best efficacy.Drug tolerance of Mycophenolate mofetil is better than that of Rituximab, and that of Cyclophosphamide remains the worst.Azathioprine is not recommended as the first-line drug of NMOSD because of frequent adverse events and the slow onset.This study aims to review the sequential immunotherapy of NMOSD in children.